Results of Neoteam: A randomized multicenter phase II study of liposomal doxorubicin hydrochloride plus trastuzumab vs conventional doxorubicin both in combination with cyclophosphamide and followed by docetaxel plus trastuzumab as neoadjuvant treatment of HER2-positive primary breast cancer

被引：0
|
作者：
Pernas Simon, S. [1 ]
Rezai, M. [2 ]
Hauschild, M. [3 ]
Machiels, J. P. [4 ]
Paepke, S. [5 ]
Llombart Cussac, A. [6 ]
机构：
[1] Inst Catala Oncol, Dept Oncol, Barcelona, Spain
[2] Luis Hosp, Dept Obstet & Gynaecol, European Breast Ctr, Dusseldorf Med Ctr, Dusseldorf, Germany
[3] Frauenklin, Dept Obstet & Gynaecol, Rheinfelden, Switzerland
[4] Clin Univ St Luc, Dept Oncol, Brussels, Belgium
[5] Sankt Gertrauden Krankenhaus, Dept Breast Surg, Berlin, Germany
[6] IDIBELL, Inst Catala Oncol, Dept Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw365.72
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
293P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II Trial of Neoadjuvant Pegylated Liposomal Doxorubicin with Paclitaxel and Trastuzumab in Patients with Operable Her2-Positive Breast Cancer
    Hyams, D. M.
    Leichman, G. C.
    Klein, P.
    Rietchsel, P.
    Levine, E. G.
    Gebski, V. J.
    Kelley, M. A.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 570S - 570S
  • [22] Lapatinib-plus-Pegylated Liposomal Doxorubicin in Advanced HER2-positive Breast Cancer Following Trastuzumab. A Phase II Trial
    Pircher, Magdalena
    Mlineritsch, Brigitte
    Fridrik, Michael A.
    Dittrich, Christian
    Lang, Alois
    Petru, Edgar
    Weltermann, Ansgar
    Thaler, Josef
    Hufnagl, Clemens
    Gampenrieder, Simon Peter
    Rinnerthaler, Gabriel
    Ressler, Sigrun
    Ulmer, Hanno
    Greil, Richard
    [J]. ANTICANCER RESEARCH, 2015, 35 (01) : 517 - 521
  • [23] Docetaxel, cyclophosphamide and trastuzumab as neoadjuvant chemotherapy in HER2-positive primary breast cancer.
    Nakatsukasa, Katsuhiko
    Taguchi, Tetsuya
    Sugimoto, Riho
    Sakaguchi, Kouichi
    Kotani, Tatsuya
    Hukuda, Kenichirou
    Kawakami, Sadao
    Hujiwara, Ikuya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification
    Saracchini, S.
    Foltran, L.
    Tuccia, F.
    Bassini, A.
    Sulfaro, S.
    Micheli, E.
    Del Conte, A.
    Bertola, M.
    Gion, M.
    Lorenzon, M.
    Tumolo, S.
    [J]. BREAST, 2013, 22 (06): : 1101 - 1107
  • [25] Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: A randomized phase II study (METIS)
    Xia, Wen
    Yuan, Zhongyu
    Wang, Shusen
    Zheng, Qiufan
    Wu, Zhiyong
    Zhong, Muyi
    Xu, Fei
    Wang, Ying
    Ma, Xiaopeng
    Ma, Shihui
    Zhang, Yuan-Qi
    Zhang, Lehong
    Shi, Yanxia
    Huang, Heng
    Xu, Xiangdong
    Li, Haiyan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
    Baselga, J.
    Manikhas, A.
    Cortes, J.
    Llombart, A.
    Roman, L.
    Semiglazov, V. F.
    Byakhov, M.
    Lokanatha, D.
    Forenza, S.
    Goldfarb, R. H.
    Matera, J.
    Azarnia, N.
    Hudis, C. A.
    Rozencweig, M.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (03) : 592 - 598
  • [27] Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC®T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients:: BCIRG 006 study
    Slamon, D
    Eiermann, W
    Robert, N
    Pienkowski, T
    Martin, M
    Pawlicki, M
    Chan, A
    Smylie, M
    Liu, M
    Falkson, C
    Pinter, T
    Fornander, T
    Shiftan, T
    Valero, V
    Von Minckwitz, G
    Mackey, J
    Tabah-Fisch, J
    Buyse, M
    Lindsay, MA
    Riva, A
    Bee, V
    Pegram, M
    Press, M
    Crown, J
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S5 - S5
  • [28] Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase Ⅱ single-arm study
    Yaping Yang
    Liang Jin
    Yudong Li
    Nanyan Rao
    Chang Gong
    Shunrong Li
    Jiannan Wu
    Jinghua Zhao
    Linxiaoxiao Ding
    Fengxia Gan
    Jun Zhang
    Ruifa Feng
    Zhenzhen Liu
    Qiang Liu
    [J]. Chinese Journal of Cancer Research, 2024, 36 (01) : 55 - 67
  • [29] Neoadjuvant pyrotinib plus trastuzumab, docetaxel, and carboplatin in patients with HER2-positive early breast cancer: A single-group, multicenter, phase II study
    Liu, Z.
    Zhu, J.
    Wang, C.
    Sun, X.
    Lu, Z.
    Chen, X.
    Wang, H.
    Mao, S.
    Zhou, Y.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S331 - S331
  • [30] A phase II single-arm clinical study of neoadjuvant treatment with pegylated liposomal doxorubicin (PLD) plus cyclophosphamide (C) combined with trastuzumab (H) and pertuzumab (P) in HER2-positive (HER2+) breast cancer (BC)
    Yang, Y.
    Jin, L.
    Rao, N.
    Gong, C.
    Li, S.
    Li, Y.
    Wu, J.
    Zhao, J.
    Ding, L.
    Liu, Q.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S624 - S624
12345